Torben:
I don't want them to sell shares at $19. I want them to very clearly communicate their business plan to the street and investors, and then sell shares at $60.
Damn it. I just want some clear communications about the company's potential and plans.
Or, forget selling shares -- do a "Leukocyte". Or, do a "Chiron". My point is, FRIGGING do something, Dausch!
We have one of the most leveraged business plans in biotech, and these guys are just sitting and floundering, making like sitting ducks.
Grrrrrrrr.................
But, I agree with you, fully..... the last thing that the company should do now is sell shares after this protracted mess.
Never, ever have I seen a management team fail to make a transition like this team has failed. In 1998, I was indicating that the name Oesterling might make it, someday, side-by-side with Rathman and Johnson. *Poof*, opposite end of spectrum.
Rick |
